Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06993792 · ClinicalTrials.gov registry record · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
- 20
- Study locations
NCT06993792 is a Phase 3 study of Obesity and Type 2 Diabetes that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,200 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06993792, a Phase 3 study of Obesity and Type 2 Diabetes, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Florida
- Accel Research Sites - DeLand Clinical Research Unit - DeLand
- Innovation Medical Research Center - Fort Lauderdale - Fort Lauderdale
- Indago Research & Health Center, Inc - Hialeah
- Encore Medical Research - Hollywood
- West Orange Endocrinology P.A. - Ocoee
- Care Access - Tampa - Tampa
- Conquest Research - Winter Park
Georgia
- Accel Research Sites - NeuroStudies Clinical Research Unit - Decatur
- Care Access - Decatur - Decatur
- Javara - Privia Medical Group Georgia - Savannah - Savannah
- North Georgia Clinical Research - Woodstock
California
- Norcal Endocrinology & Internal Medicine - San Ramon
- Southern California Clinical Research - Santa Ana
- Care Access - Thousand Oaks - Thousand Oaks
Arizona
- Clinical Research Institute of Arizona (CRI) - Sun City West - Sun City West
- Novak Clinical Research - Tucson - North La Cholla Boulevard - Tucson
Maryland
- Endocrine and Metabolic Consultants - Rockville
- Javara - Privia Medical Group - Silver Spring - Silver Spring
Idaho
- Solaris Clinical Research - Meridian
Louisiana
- Care Access - New Iberia - New Iberia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06993792
The ClinicalTrials.gov registry entry for NCT06993792 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (47% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06993792 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Georgia, California.
Frequently Asked Questions
What is clinical trial NCT06993792 about?
NCT06993792 is a clinical study titled "A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes". The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into eithe...
What is the current status of trial NCT06993792?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2025-05-15. Estimated completion is 2027-08.
What conditions does trial NCT06993792 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight.
What interventions are being tested in trial NCT06993792?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT06993792?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06993792 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.